However, it is important to note that there is no official clinical evidence establishing that GLP-1 medications impair pancreatic enzyme production or secretion
Each stack page includes comparison context showing pathway coverage, evidence strength, and tradeoffs
What are the possible side effects associated with taking a GLP-1 agonist
In animal models, activation of these receptors has been shown to modulate neuronal firing patterns and the KNDy (kisspeptin/neurokinin B/dynorphin) network, thereby influencing GnRH/LH pulsatility and estrous cyclicity (8991)
Non-prescription and compounded peptides such as BPC-157, CJC-1295/Ipamorelin, AOD-9604, and MOTS-c are not FDA-approved for weight loss and lack the same regulatory oversight and clinical safety data as the GLP-1 drugs in the table above, which is why they should only be used under the guidance of a licensed medical provider who can order lab work, personalize dosing, and monitor for side effects throughout treatment
There is also uncertainty over the long-term effects of GLP-1 receptor agonists for weight management in those without diabetes
